Altimmune to Present at Upcoming Investor Conferences

Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022:

• H.C. Wainwright Global Investment Conference
  Tuesday, May 24, 2022
  7:00 am Eastern Time
  The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

• B. Riley Securities Institutional Investor Conference
  Thursday, May 26, 2022
  1:00 pm Pacific Time
  The session will be an in person fireside chat.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

What investor conferences is Altimmune participating in May 2022?

Altimmune will attend the H.C. Wainwright Global Investment Conference on May 24 and the B. Riley Securities Institutional Investor Conference on May 26.

What is the date and time of the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference will be on May 24, 2022, at 7:00 am Eastern Time.

When will the B. Riley Securities Institutional Investor Conference take place?

The B. Riley Securities Institutional Investor Conference is scheduled for May 26, 2022, at 1:00 pm Pacific Time.

What is pemvidutide (ALT-801) developed by Altimmune?

Pemvidutide (ALT-801) is a GLP-1/glucagon dual receptor agonist for treating obesity and NASH.

What therapeutic areas does Altimmune focus on?

Altimmune specializes in developing treatments for obesity and liver diseases.